AcquiSci Receives Award from Hackensack University Medical Center to Research Company's Patented Anti-Inflammatory d-OSAB™ Technology
AcquiSci and Hackensack University Medical Center to Collaborate on Investigating the Therapeutic Potential of the d-OSAB Medical Device-Based Anti-Inflammatory Platform Technology in a Preclinical Stroke Study Program
NEWARK, N.J., June 11, 2012 /PRNewswire/ -- AcquiSci Inc., www.acquisci.com, today announced it has received an award from the Hackensack University Medical Center to research AcquiSci's patented d-OSAB™ technology as a device-based approach to modulating inflammation. This preclinical study represents Phase I of a three Phase study program, and will evaluate the safety and efficacy of oxidative stress on apoptotic leukocyte induction and subsequent inflammatory cytokine modulation. The overall program is designed to transition into a clinical stroke porcine model with primary clinical endpoints paralleling those typical in a human efficacy trial for translational relevance. This project is being funded by the U.S. Department of Defense in support of development of candidate treatment approaches for traumatic brain injury resulting from military operations.
Dr. Chinwe Ogedegbe, Section Chief, Research Emergency Trauma Department at HackensackUMC, will be the Principal Investigator. AcquiSci will work closely with HackensackUMC by participating in the study design and investigator meetings.
AcquiSci's CEO and inventor of the technology, Joseph Latino, stated, "This is an excellent opportunity to rigorously confirm the ability of AcquiSci's technology to reduce inflammation that is the underpinning of many diseases, in particular, traumatic brain injury. Using the porcine stroke model, we believe that we can conclusively demonstrate a reduction in the inflammation surrounding the clot commonly attributed as a major causative phenomenon resulting in loss of cognitive and motor function loss in ischemic stroke. Positive results in inflammation reduction in stroke modeling may be applied to traumatic brain injury and in particular, useful in military applications. HackensackUMC recognized the importance of this common inflammatory component and we are fortunate to have been able to establish this noteworthy affiliation."
About Hackensack University Medical Center
Hackensack University Medical Center, a 775-bed teaching and research hospital affiliated with the University of Medicine and Dentistry of New Jersey -- New Jersey Medical School, is the largest provider of inpatient and outpatient services in the state of New Jersey. Founded in 1888 with 12 beds and as Bergen County's first hospital, Hackensack University Medical Center has demonstrated more than a century of growth and progress. Today, this not-for-profit, tertiary-care, teaching and research hospital serves as the hub of healthcare for northern New Jersey and the New York metropolitan area. Hackensack University Medical Center continues to grow in response to the needs of its patient population.
AcquiSci Inc., a privately-held New Jersey corporation, incorporated in December 2007, is developing its medical device-based technology with an anti-inflammatory therapeutic platform known as d-OSAB™ (doseable-Oxidative Stressed Autologous Blood) that will appreciably widen the present window of treatment for ischemic stroke. The device has applications for other clinical indications, including Chronic Heart Failure, where inflammation is an underlying cause of disease, and as a purification process for the production of pathogen-free biologics, i.e. the inactivation of infectious prions, the rogue protein attributed to Mad Cow and Creutzfeldt-Jakob diseases.
For inquiries, please contact:
Linda Sharkus, PhD
Chinwe Ogedegbe, M.D., MPH
Section Chief, HackensackUMC Emergency Trauma Department
SOURCE AcquiSci Inc.Back to top